Dopo i grandi trial sui NAO: studi post-marketing,registri e dati dal mondo reale Dr. Claudio Fresco Responsabile Scientifico Dipartimento Scienze Cardiopolmonari, AOUD Presidente Eletto, ATBV www.atbv.com Disclosures • Relatore a congressi sponsorizzati da Boehringer Ingelheim, Bayer, Pfizer, BMS, Daiichi Sankyo • Responsabile Scientifico del sito www.pantareionline.it, supportato da un grant incondizionato di Boehringer www.atbv.com Ingelheim I trials ci sono stati presentati bene?? www.atbv.com Primary Efficacy Outcome: Stroke and Systemic Embolism www.atbv.com Haemorrhagic Stroke www.atbv.com Dove sta il problema? www.atbv.com Haemorrhagic Stroke www.atbv.com Non haemorragic stroke www.atbv.com Systemic Embolism www.atbv.com Major Bleeding www.atbv.com Major Gastrointestinal Bleeding www.atbv.com Concludendo 1. Dabigratran 150 mg bid is more effective in preventing SSE than W without significantly increasing MB. 2. Dabigatran 110 mg bid is non-inferior to warfarin for the prevention of SSE and causes less MB. 3. Rivaroxaban is non-inferior to W for the prevention of SSE without significantly increasing MB. 4. Apixaban is superior to W in preventing SSE, reducing bleeding and mortality. 5. Edoxaban 60 mg is non-inferior to W for the prevention of SSE, reduces the risk of MB and CV death. 6. Edoxaban 30 mg is non-inferior to W for the prevention of SSE, reduces the risk of MB and CV death. www.atbv.com I pazienti dei trials sono gli stessi che vediamo ogni giorno? www.atbv.com Lee S et al. BMJ Open 2012; www.atbv.com • The source population for this research, that is, the General Practice Research Database (GPRD) is the largest primary care database in the world. • 83.898 patients included in the analysis www.atbv.com Drug Eligible ChadsVasc 68% Eligible CHADS 74% Apixaban 65% 72% Rivaroxaban 51% 56% Dabigatran www.atbv.com * Thromb Haemost 2012; 107: 584–589 www.atbv.com Approccio Teorico: Stroke Ischemico Thromb Haemost 2012; 107: 584–589 www.atbv.com Approccio Teorico: ICH Thromb Haemost 2012; 107: 584–589 www.atbv.com Approccio Teorico Net Clinical benefit Thromb Haemost 2012; 107: 584–589 www.atbv.com Il Mondo Reale… DABIGATRAN www.atbv.com Real-world evidence from >200 000 patients is largely consistent with the results from RE-LY® Positive safety and efficacy profile of dabigatran vs warfarin confirmed in: FDA study of >134 000 US Medicare patients1 >25 000 pts from US Department of Defense database2 >38 000 pts from two large US health insurance databases3 >20 000 pts from independent Danish observational studies4,5 In the USA, the licensed doses for Pradaxa® are: Pradaxa® 150 mg BID and Pradaxa® 75 mg BID for the prevention of stroke and systemic embolism in adult patients with nonvalvular AF. Pradaxa® 110 mg BID is indicated for certain patients in Europe, and was shown to be as effective as warfarin in preventing stroke or systemic embolism. 1. Available at www.fda.gov/Drugs/DrugSafety/ucm396470.htm; accessed September 2014; 2. Villines TC et al. AHA 2014; 3. Seeger JD et al. AHA 2014; 4. Larsen TB et al. Am J Med 2014;127:650–6.e5; 5. Larsen TB et al. Am J Med 2014;127:329– 36.e4 22 SPAF Safety and efficacy of dabigatran are maintained long-term in the RELY-ABLE® extended follow-up trial Rates of major bleeding remained consistent over 6.7 years of follow-up Dabigatran 150 mg BID Cumulative risk 0.25 0.20 0.15 Stroke/SE remained low Dabigatran 110 mg BID 0.25 D150: 3.34%/yr D110: 2.76%/yr HR: 1.22; 95% CI: 1.08–1.37 0.20 0.15 0.10 0.10 0.05 0.05 0.0 0.0 0 1 2 3 4 D150: 1.25%/yr D110: 1.54%/yr HR: 0.81; 95% CI: 0.68–0.96 5 6 0 1 2 3 4 5 6 Time from randomization (years) Time from randomization (years) No at risk: D110 6015 5616 4075 2658 2085 903 158 6015 5706 4190 2737 2147 929 157 D150 6076 5622 4130 2638 2077 910 146 6076 5774 4276 2753 2181 953 149 Connolly S et al. Circulation 2013;128:237–43; Ezekowitz M. AHA 2013; abstr 10684 23 ‘EU label’ analysis assessed outcomes when dabigatran was used according to EU label recommendations Full RE-LY® population (n=18 113) Patients fully randomized: Post-hoc analysis of patients’ baseline characteristics D150 D110 recommended recommended population (71.4%)* population (28.6%)* Received D110 (under-treated) n=4307 Received D110 (recommended) n=1708 n=6076 Received D150 (recommended) n=4296 Received D150 (over-treated) n=1780 Warfarin n=6022 Received warfarin n=4324 Received warfarin n=1698 D110 n=6015 D150 <80 years and HAS-BLED <3 OR verapamil SPAF Post-hoc pooled population ‘EU label simulated dabigatran’ vs warfarin Dabigatran recommended dose Warfarin ≥80 years OR HAS-BLED ≥3 OR verapamil *Percentages expressed as proportion of total RE-LY® population Lip GY et al. Thromb Haemost 2014;111:933–42 24 ‘EU label-compliant’ dabigatran treatment provides a meaningful and clinically relevant benefit over warfarin Source SPAF HR vs warfarin Efficacy endpoints (ITT) Primary: stroke/SE Ischaemic stroke Haemorrhagic stroke Death Vascular death MI Safety endpoints (safety set) MBE 0.74 (0.60–0.91) 0.91 (0.72–1.15) 0.22 (0.11–0.44) 0.86 (0.75–0.98) 0.80 (0.68–0.95) 1.14 (0.83–1.55) 0.85 (0.73–0.98) Life-threatening MBE ICH GI MBE Any bleeds 0.72 (0.58–0.91) 0.28 (0.17–0.45) 1.23 (0.96–1.59) 0.86 (0.81–0.92) 0.1 1 Favours dabigatran 1.6 Favours warfarin Stroke/SE Major bleed Mortality RR (95% CI) RR (95% CI) RR (95% CI) 0.74 (0.60–0.91) 0.85 (0.73–0.98) 0.86 (0.75–0.98) Data from EU label simulated dabigatran treatment analysis. Patients received dabigatran 150 mg BID or 110 mg BID according to EU label recommendations ITT, intention to treat; MBE, major bleeding event Lip GY et al. Thromb Haemost 2014;111:933–42 25 Independent FDA study of Medicare patients analysed outcomes in >134 000 new users of dabigatran or warfarin • Observational cohort study • US Medicare database • Comparison of ischaemic stroke, ICH, major GI bleeding, acute MI, and mortality rates using insurance-claim and administrative data Study period 2010 2011 2012 • >134 000 new users (OAC treatment-naïve) of dabigatran or warfarin • All recently diagnosed with AF • All aged ≥65 years • 37 500 person-years of follow-up • Adjustments were made for confounding variables In the USA, the licensed doses for Pradaxa® are: Pradaxa® 150 mg BID and Pradaxa® 75 mg BID for the prevention of stroke and systemic embolism in adult patients with nonvalvular AF Graham DJ et al. Circulation 2015;131:157-64 26 Independent FDA Medicare analysis findings support favourable benefit–risk profile of dabigatran shown in RE-LY®* HR: 0.97 P=0.50 Incidence rate per 100 person-years Medicare1 Warfarin 5 4 3 2 Dabigatran 150 mg & 75 mg BID combined HR: 0.80 P=0.02 HR: 0.86 P=0.006 HR: 1.28 P<0.001 HR: 0.92 P=0.29 HR: 0.34 P<0.001 1 0 4 Event rate (% per year) RE-LY®2–5 5 Warfarin Dabigatran 150 mg BID 3 2 RR: 0.76 P=0.04 1 RR: 0.88 P=0.05 RR: 0.94 P=0.41 RR: 1.48 P=0.001 RR: 0.41 P<0.001 RR: 1.27 P=0.12 0 Ischaemic stroke ICH Major bleeding GI bleeding MI Mortality In the USA, the licensed doses for Pradaxa® are: Pradaxa® 150 mg BID and Pradaxa® 75 mg BID for the prevention of stroke and systemic embolism in adult patients with nonvalvular AF. Pradaxa® 110 mg BID is indicated for certain patients in Europe, and was shown to be as effective as warfarin in preventing stroke or systemic embolism. RE-LY® was a PROBE (prospective, randomized, open-label with blinded endpoint evaluation) study *Primary findings for dabigatran are based on analysis of both 75 mg and 150 mg together without stratification by dose. Numbers above bars denote HRs vs warfarin. 1. Graham DJ et al. Circulation 2015;131:157-64; 2. Connolly SJ et al. N Engl J Med 2009;361:1139–51; 3. Connolly SJ et al. N Engl J Med 2010;363:1875–6; 4. Pradaxa®: EU SPC, 2014; 5. Connolly SJ et al. N Engl J Med 2014; 371:1464–5 27 Favourable benefit–risk profile of dabigatran supported by real-world evidence: US Department of Defense database HR (95% CI) • Observational study (Oct 2010 to Jul 2012) • US DoD database Stroke 0.73 (0.55–0.97) Ischaemic stroke 0.84 (0.62–1.13) Haemorrhagic stroke 0.32 (0.14–0.73) Major bleeding • >25 000 new users of dabigatran or warfarin available for matching • All NVAF patients • Aged 18–89 years at index date 0.87 (0.74–1.02) Major ICH 0.49 (0.30–0.79) Major GI bleeding 1.13 (0.94–1.37) MI 0.65 (0.45–0.95) Death 0.64 (0.55–0.74) 0.0 0.5 1.0 Favours dabigatran Pradaxa® Pradaxa® Pradaxa® In the USA, the licensed doses for are: 150 mg BID and of stroke and systemic embolism in adult patients with nonvalvular AF Comparison groups (each n=12 793) established using propensity score matching Villines TC et al. AHA 2014 1.5 2.0 Favours warfarin 75 mg BID for the prevention 28 Favourable benefit–risk profile of dabigatran supported by real-world evidence: independent Danish registry VKA-naïve stratum • Observational cohort study (Aug 2011 to May 2013) • Nationwide Danish registries • 11 315 first-time dabigatran users (7063 VKA-naïve) vs 22 630 matched warfarin users • VKA-naïve = ≥2 years since last warfarin purchase • All AF patients D110 vs W D150 vs W HR* (95% CI) Any 0.72 (0.59–0.88) Major 0.93 (0.74–1.16) Fatal 0.52 (0.28–0.95) GI 0.50 (0.27–0.94) ICH 0.30 (0.17–0.54) Any 0.68 (0.55–0.84) Major 0.67 (0.53–0.85) Fatal 0.70 (0.33–1.52) GI 1.45 (0.84–2.50) ICH 0.33 (0.17–0.66) 0.10 0.50 1.00 2.00 5.00 Favours dabigatran Favours warfarin *Adjusted HR: age, components of CHA2DS2-VASc, HAS-BLED, months since August 2011, time since initiation of VKA therapy; W, warfarin Larsen TB et al. Am J Med 2014;127:650–6.e5 29 Il Mondo Reale… RIVAROXABAN www.atbv.com Il Mondo Reale… RIVAROXABAN www.atbv.com Major Bleeds Rocket AF Dresden Registry 3.6 3.1 www.atbv.com www.atbv.com Current Medical Research & Opinion 2014, 1–9 www.atbv.com www.atbv.com Il Mondo Reale… Apixaban www.atbv.com Apixaban Terzo NOAC, approvato da meno tempo rispetto a dabigatran e rivaroxaban. Non ci sono motivi per pensare che nel mondo reale debba comportarsi in modo diverso rispetto agli altri due NOAC www.atbv.com Conclusioni 1. Contrariamente a quello che solitamente succede, dove i risultati dei trials sono in parte mitigati dalle analisi dei registri, nel caso dei NOAC i registri confermano e anche amplificano i benefici osservati negli studi registrativi 2. Non dobbiamo quindi aver paura di utilizzare questi farmaci, perché a lungo termine i benefici saranno evidenti www.atbv.com